Treatment of a metabolic liver disease by <i>in vivo</i> prime editing in mice
Desirée Böck(University of Zurich), Gerald Schwank(University of Zurich), Zacharias Kontarakis(ETH Zurich), Lukas Schmidheini(University of Zurich), Hiu Man Grisch‐Chan(University Children's Hospital Zurich), Lukas Villiger(McGovern Institute for Brain Research), Tanja Rothgangl(University of Zurich), Nicole Rimann(University Children's Hospital Zurich), Susanne Kreutzer(University of Zurich), Nicholas Mathis(University of Zurich), Beat Thöny(University of Zurich), Eleonora Ioannidi(University of Zurich)
Cited by 3
Related Papers
Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing
|New England Journal of Medicine|2020|801
In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
|Nature Biotechnology|2021|375
In vivo prime editing of a metabolic liver disease in mice
|Science Translational Medicine|2022|184
Predicting prime editing efficiency and product purity by deep learning
|Nature Biotechnology|2023|145